BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16369496)

  • 1. DBC1 re-expression alters the expression of multiple components of the plasminogen pathway.
    Louhelainen JP; Hurst CD; Pitt E; Nishiyama H; Pickett HA; Knowles MA
    Oncogene; 2006 Apr; 25(16):2409-19. PubMed ID: 16369496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of the plasminogen activator system by mechanical stimulation of human bronchial epithelial cells.
    Chu EK; Cheng J; Foley JS; Mecham BH; Owen CA; Haley KJ; Mariani TJ; Kohane IS; Tschumperlin DJ; Drazen JM
    Am J Respir Cell Mol Biol; 2006 Dec; 35(6):628-38. PubMed ID: 16794260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
    Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
    Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors.
    Guda K; Claffey KP; Dong M; Nambiar PR; Rosenberg DW
    Mol Carcinog; 2003 May; 37(1):51-9. PubMed ID: 12720300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Common genetic variants in the plasminogen activation pathway are not associated with multiple sclerosis.
    Cox MB; Bowden NA; Scott RJ; Lechner-Scott J
    Mult Scler; 2014 Apr; 20(4):489-91. PubMed ID: 23897640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
    Foca C; Moses EK; Quinn MA; Rice GE
    Gynecol Oncol; 2000 Nov; 79(2):244-50. PubMed ID: 11063652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas.
    Benassi MS; Ponticelli F; Azzoni E; Gamberi G; Pazzaglia L; Chiechi A; Conti A; Spessotto P; Scapolan M; Pignotti E; Bacchini P; Picci P
    Histol Histopathol; 2007 Sep; 22(9):1017-24. PubMed ID: 17523079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
    Sprague LD; Tomaso H; Mengele K; Schilling D; Bayer C; Stadler P; Schmitt M; Molls M
    Oncol Rep; 2007 May; 17(5):1259-68. PubMed ID: 17390074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.
    Biliran H; Sheng S
    Cancer Res; 2001 Dec; 61(24):8676-82. PubMed ID: 11751384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cAMP-ERK1/2 signaling pathway regulates urokinase-type plasminogen activator-induced bovine granulosa cell proliferation.
    Zhao Y; Yu B; Liu X; Hu J; Yang Y; Namei E; Yang B; Bai Y; Qian Y; Li H
    Reproduction; 2020 Dec; 160(6):853-862. PubMed ID: 33112787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UVB increases urokinase-type plasminogen activator receptor (uPAR) expression.
    Marschall C; Lengyel E; Nobutoh T; Braungart E; Douwes K; Simon A; Magdolen V; Reuning U; Degitz K
    J Invest Dermatol; 1999 Jul; 113(1):69-76. PubMed ID: 10417621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
    Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
    Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.
    Los M; Zeamari S; Foekens JA; Gebbink MF; Voest EE
    Cancer Res; 1999 Sep; 59(17):4440-5. PubMed ID: 10485495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
    Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
    Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinoic acid upregulates the plasminogen activator system in human epidermal keratinocytes.
    Braungart E; Magdolen V; Degitz K
    J Invest Dermatol; 2001 May; 116(5):778-84. PubMed ID: 11348470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two PstI polymorphisms for the urokinase-type plasminogen activator receptor gene (PLAUR).
    Børglum AD; Byskov A; Roldan AL; Kruse TA
    Hum Genet; 1992 Jul; 89(5):584. PubMed ID: 1353059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor.
    Albo D; Rothman VL; Roberts DD; Tuszynski GP
    Br J Cancer; 2000 Aug; 83(3):298-306. PubMed ID: 10917542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
    Warnecke-Eberz U; Prenzel KL; Baldus SE; Metzger R; Dienes HP; Bollschweiler E; Hoelscher AH; Schneider PM
    Pancreas; 2008 Mar; 36(2):173-7. PubMed ID: 18376309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
    Ecke TH; Schlechte HH; Schulze G; Lenk SV; Loening SA
    Anticancer Res; 2005; 25(1B):635-41. PubMed ID: 15816639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.